Ultragenyx Pharmaceutical (RARE) stock continues to trade with recent moves shaped largely by its rare disease portfolio and late stage pipeline. This has prompted investors to reassess risk, growth potential, and current valuation
At a share price of $29.28, Ultragenyx Pharmaceutical has seen short term pressure, with a 1 day share price return down 3.11% and 7 day share price return down 13.42%. This is set against a 90 day share price return of 18.02% and year to date share price return of 24.07%, while the 1 year total shareholder return of 11.29% contrasts with a weaker 3 year total shareholder return, suggesting improving momentum from a still recovering base
If you are weighing rare disease opportunities like Ultragenyx Pharmaceutical against other growth stories in healthcare, it can be useful to scan for companies applying AI to the sector
For Ultragenyx Pharmaceutical, the recent pullback comes after a stronger multi month recovery, leaving investors to debate whether the stock is catching up with the rare disease business or simply reflecting another swing in sentiment before valuation is reconsidered
Advertisement
Most Popular Narrative: 43.7% Undervalued
Ultragenyx Pharmaceutical’s most followed narrative places fair value at $52.05 against the latest close of $29.28, framing a wide gap that hinges on rare disease and gene therapy execution
The accelerating global identification and diagnosis of rare diseases, supported by advancements in genomics and genetic testing, are expanding the addressable patient pool for Ultragenyx’s existing and future therapies, which should drive sustained long-term revenue growth
Healthcare payers and regulatory agencies are increasingly recognizing the value of orphan drugs, as evidenced by faster development timelines (FDA Breakthrough Therapy designation for GTX-102) and ongoing pricing or reimbursement wins in regions like Latin America and EMEA, supporting robust revenue streams and pricing power over the next several years
Curious what sits behind that fair value gap for Ultragenyx Pharmaceutical? The narrative focuses on expectations for revenue expansion, margin improvement, and a future earnings profile that assumes meaningful progress across several late stage programs. The specific path and mix of factors underlying those projections are key to the valuation
Result: Fair Value of $52.05 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts
However, investors also need to weigh the risk that continued losses and higher cash use, along with potential regulatory setbacks for programs like UX111, could challenge this Ultragenyx Pharmaceutical narrative
Find out about the key risks to this Ultragenyx Pharmaceutical narrative
Another View: What Multiples Say About Ultragenyx Pharmaceutical
While the narrative points to a large gap between price and fair value for Ultragenyx Pharmaceutical, the current P/S ratio of 4.3x sends a more mixed signal. It screens cheaper than the US Biotechs industry at 11.1x and peer average at 8.4x, yet it sits above the fair ratio of 2.7x. This suggests the market could still compress the multiple if expectations are not met. How comfortable are you with that trade off between potential upside and valuation risk?
See what the numbers say about this price — find out in our valuation breakdown
Next Steps
With mixed signals around Ultragenyx Pharmaceutical’s valuation and outlook, it may be helpful to act promptly and consider both sides yourself using the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Ultragenyx Pharmaceutical?
Do not stop with Ultragenyx Pharmaceutical. Broaden your watchlist with a few focused stock ideas that line up with how you like to balance risk and reward
- Zero in on potential bargains by reviewing companies that screen as 47 high quality undervalued stocks before they attract wider attention.
- Strengthen your income focus by checking stocks in the 8 dividend fortresses and see which yields might complement your growth positions.
- Dial back overall portfolio risk by searching for companies highlighted in the 84 resilient stocks with low risk scores so you are not relying on just one story.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities
• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:RARE
Ultragenyx Pharmaceutical
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific
See The Free Research Report
High growth potential and good value
See The Free Research Report
Similar Companies
NasdaqGS:ALNY
Alnylam Pharmaceuticals
NasdaqGS:BIIB
Biogen
Market Insights
A brand’s strength doesn’t always lastRichard Bowman
What makes a lasting brand?Andrew Legget
Q-Day: The risk the market forgot to repriceRichard Bowman
Advertisement
Weekly Picks
DA
davidlsanderon Nevgold·10 days ago
The U.S. Government Is Desperate for This Metal. This Tiny Miner Has It — Its Closest Peer Is Already Worth Double
Fair Value:US$2.1946.6% undervalued
31followersusers have followed this narrative
·0commentsusers have commented on this narrative
·2likesusers have liked this narrative
BE
benjamin_lvieqon PayPal Holdings·3 days ago
PayPal: PayPal Doesn’t Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6513.0% undervalued
60followersusers have followed this narrative
·2commentsusers have commented on this narrative
·9likesusers have liked this narrative
JD
JD009on Celsius Holdings·5 months ago
From $5M to $2B: Why the 2024 Crash Was the Best Buying Opportunity in Consumer Stocks
Fair Value:US$55.4347.7% undervalued
20followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
WA
Wavefareron Accenture·7 days ago
High-quality global services company facing an AI-driven valuation reset
Fair Value:US$30152.3% undervalued
16followersusers have followed this narrative
·1commentusers have commented on this narrative
·5likesusers have liked this narrative
RecentlyUpdated Narratives
DS
DS2investon PayPal Holdings·about 11 hours ago
PayPal: Undervalued Cash Flow Machine or Value Trap?
Fair Value:US$69.0318.1% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
MI
MineStackron AbraSilver Resource·about 12 hours ago
NAV $4B CAD
Fair Value:CA$3661.2% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
CE
CentryResearchon Centrus Energy·about 13 hours ago
Centrus Energy: The Next Nuclear Bottleneck Isn’t Reactors. It’s Fuel
Fair Value:US$19017.9% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
IN
Investingwillyon Mastercard·29 days ago
Mastercard: The Best Dividend Stock You’re Ignoring
Fair Value:US$75027.5% undervalued
96followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
BL
BlackGoaton Cerebras Systems·26 days ago
The Wafer Giant Threatening NVIDIA’s GPU Hegemony
Fair Value:US$415.5458.4% undervalued
63followersusers have followed this narrative
·3commentsusers have commented on this narrative
·11likesusers have liked this narrative
BEbenjamin_lvieqon PayPal Holdings·3 days ago
PayPal: PayPal Doesn’t Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6513.0% undervalued
60followersusers have followed this narrative
·2commentsusers have commented on this narrative
·9likesusers have liked this narrative
